Technology

January 19, 1999SuperGen to acquire oncology portfolio of Sparta Pharmaceuticals
September 24, 1998$850,000 Awarded to Sparta Pharmaceuticals, Inc.
June 24, 1998SpartajectTM Busulfan Phase I Trial in Pediatric Patients Begins at
St . Jude Children's Research Hospital
June 11, 1998SpartajectTM Busulfan Phase I Trial in Patients with Neoplastic Meningitis Begins at Duke University Medical Center
June 1, 1998Sparta Pharmaceuticals, Inc. Completes Patient Enrollment for RII Retinamide Phase I/II trial
May 28, 1998Sparta Pharmaceuticals, Inc. Receives FDA Approval to Begin Phase II/III SpartajectTM busulfan Clinical Trials
May 13, 1998Sparta Pharmaceuticals, Inc. Successfully Completes Phase I SpartajectTMbusulfan Clinical Trial
April 22, 1998Sparta Pharmaceuticals, Inc. Signs Drug Delivery Pact with Schering-Plough Corporation
April 1, 1998Sparta Pharmaceuticals, Inc. Announces Clinical Findings at American Association for Cancer Research Conference
February 23, 1998Sparta Pharmaceuticals, Inc. Announces Patent Approval From The United States Patent and Trademark Office
January 20, 1998Sparta Pharmaceuticals, Inc. Announces Agreement with the Bioprocessing Resource Center for Production of Sparta's LEX 032
December 8, 1997Sparta Pharmaceuticals, Inc. Announces The Acquisition of PZG
October 17, 1997Sparta Pharmaceuticals, Inc. Announces Patent Approval From The United States Patent and Trademark Office
July 22, 1997Sparta Pharmaceuticals, Inc. Announces Initiation of 5-FP Clinical Trial at Harper Hospital of Detroit, Michigan
July 8, 1997Sparta Pharmaceuticals, Inc. Announces Initiation of SpartajectTM Busulfan Human Clinical Trial in London, England
July 1, 1997Sparta Pharmaceuticals, Inc. and The University of Pennsylvania Announce Patent Approval From The United States Patent and Trademark Office
March 24, 1997Sparta Pharmaceuticals, Inc. Announces initiation of Busulfan Clinical Trail at Johns Hopkins Oncology Center
March 16, 1997Sparta Pharmaceuticals, Inc., in Conjunction with Yale University, Has Received Notification of Allowance of Invention, "Determination of Prodrugs Metabolizable and Therapeutic Use Thereof"
March 4, 1997Sparta Pharmaceuticals, Inc. Announces Progress of Asulacrine Trails in U.K.
February 10, 1997Sparta Pharmaceuticals, Inc. Announces 5 New Clinical Trial Sites for RII Retinamide
September 23, 1996Sparta Pharmaceuticals, Inc. and Wichita State University Announces Patent Approval For Two Novel Classes Of Serine Protease Inhibitors
September 3, 1996Sparta Pharmaceuticals, Inc. Announces Start of Clinical Trials for RII Retinamide
May 15, 1996Sparta Announces Approval of Third IND in a Year

Earnings

October 30, 1998Sparta Pharmaceuticals Reports Third Quarter Results
August 13, 1998Sparta Pharmaceuticals Reports Record Quarterly Revenues,
Improved Bottom Line Performance and Asulacrine Update
May 15, 1998Sparta Pharmaceuticals Reports First Quarter Results
March 13, 1998Sparta Pharmaceuticals Reports Fourth Quarter and 1997 Annual Results
November 7, 1997Sparta Pharmaceuticals Reports Third Quarter Results
August 8, 1997Sparta Pharmaceuticals Reports Second Quarter Results
May 14,1997Sparta Pharmaceuticals, Inc. Reports First Quarter Results
March 5, 1997Sparta Pharmaceuticals, Inc. Reports Fourth Quarter and 1996 Annual Results
November 13, 1996Sparta Pharmaceuticals, Inc. Reports Third Quarter Results
May 15, 1996Sparta Pharmaceuticals, Inc. Reports First Quarter Results

Management

March 16, 1998Sparta Pharmaceuticals, Inc. Promotes Jerry B. Hook, Ph.D., to
Chairman of The Board
September 18, 1997Sparta Pharmaceuticals, Inc. Announces The Appointment of Dr. Martin Rose
to Vice President, Clinical and Regulatory Affairs
September 24, 1996Sparta Pharmaceuticals, Inc. Announces The Appointment Of Dr. Colin Bier to The Board of Directors
June 30, 1996Sparta Pharmaceuticals, Inc. Announces New Secretary of Company
March 18, 1996Sparta Pharmaceuticals, Inc. Acquires Lexin Pharmaceuticals; New CEO, Director Named

Other

October 7, 1998Sparta Announces Receipt of Nasdaq Notice Related to Continued Listing
Requirements Company Evaluates Strategic Alternatives
June 11, 1998Sparta Returns to Original Nasdaq Trading Symbols
May 11, 1998Sparta Stockholders Approve Reverse Stock Split
September 22, 1997Sparta Pharmaceuticals, Inc. Announces Award of $750,000
August 25, 1997Sparta Pharmaceuticals Reports Change in Conversion Price of its Series B' Convertible Preferred Stock
August 28, 1996Sparta Pharmaceuticals, Inc. Reports Final Closing of Private Placement

To contact Sparta Pharmaceuticals, Please click here